Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 7.01 (Regulation FD Disclosure). All 49,263 Series A preferred shares submitted for redemption, eliminating the outstanding preferred equity overhang.
LIFECORE BIOMEDICAL, INC. DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- All 49,263 Series A preferred shares submitted for redemption, eliminating the outstanding preferred equity overhang
- Redemption obligation approximately $52.1 million due December 28, 2026, including $0.9 million accrued dividends
- March 31 liquidity $38.1 million versus redemption requirement, creating a substantial funding shortfall
- Lender consent required before payment, adding execution risk and potential covenant constraints
- Unpaid balance after December 28 incurs 1% monthly interest, increasing pressure for financing or strategic transactions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIFECORE BIOMEDICAL, INC. DE 8-K filings
Get the next LFCR 8-K as it lands
Follow LFCR for push alerts, or ask the research agent what this filing means.